Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors
Dual SIRPα/Siglec-10 inhibitor delivered intratumorally by AdV not only reinvigorated the TAM-CD8+T cell axis but also potentially reduced the risk of off-target effects. Further investigation of AdV-huSS in patients with cancer is warranted in the near future.
Authors
- Yenan Zhang
- Jiwu Wei (ORCID: https://orcid.org/0000-0002-0883-1824)
- Mengdi Wu
- Chuning Xu
- Bohao He (ORCID: https://orcid.org/0000-0003-3312-0730)
- Min Wei (ORCID: https://orcid.org/0000-0002-2649-9271)
- Peng Zou (ORCID: https://orcid.org/0000-0003-1498-842X)
- Jie Dong (ORCID: https://orcid.org/0009-0003-6513-4130)
Institutions
- Nantong University (CN)
- Nanjing Drum Tower Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-010767
- Citations
- 6
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 4.78
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Nanjing University
- State Key Laboratory of Pharmaceutical Biotechnology